Accurate patient positioning and routine computed tomography (CT) scans are critical components of proton therapy. Cone-beam CT (CBCT) has recently become available as an alternative to verification CT. This study describes the first clinical investigation of CBCT and deformable registration in adaptive lung proton therapy.
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INTRODUCTION
Lung cancer is the leading cause of cancer-related death in the United States and worldwide. Modern radiotherapy techniques allow dose escalation 1, 2 and reduced injuries to normal tissues [3] [4] [5] [6] . Proton therapy offers better dose localization than that achieved by conventional photon therapy. [7] [8] [9] [10] [11] Proton dose distribution, however, is highly sensitive to changes in patient geometry, especially in the lungs. 12 For example, interfractional tumor enlargement or development of atelectasis increase density along the beam path and shorten beam penetration. The under-ranging can potentially reduce target coverage. Conversely, tumor regression reduces density along the beam path and increases beam penetration. The over-ranging may result in unplanned dose to otherwise spared organs distal to the tumor volume. Therefore, accurate patient positioning and regular evaluation computed tomography (CT) scans are critical components of proton therapy. 13 Replanning will be required if the new dose distribution based on evaluation CTs compromises target coverage and/or exceeds tissue tolerance.
Volumetric imaging afforded by on-board cone-beam CT (CBCT) is an alternative to routine CT imaging and may play an important role in adaptive radiation therapy (ART). The advantages of onboard CBCT are threefold: (1) it offers highly accurate patient positioning in three dimensions; 14, 15 (2) it enables daily monitoring of the patient in the treatment position; and (3) and it facilitates rapid assessment of the "dose of the day". [16] [17] [18] We propose an ART workflow using on-board CBCT where replanning is triggered after three decision-points ( Fig. 1 ). First, a fast range-corrected dose distribution based on water equivalent thickness (WET) is calculated on a virtual CT (vCT) derived from the CBCT. 19 When significant dosimetric changes are observed, treatment may continue if normal tissue dose limits are not exceeded and after consultation with a physician. However, an offline review is triggered for a full dose recalculation on the vCT. If the dosimetric impact is still evaluated as significant, a rescan CT (rCT) is scheduled. If dosimetric changes are confirmed on the rCT, a replan is triggered. We retrospectively evaluated this workflow for twenty consecutive lung cancer patients summarizing common radiationinduced changes in the lung and critically assessed the workflow. The rCT was used as the goldstandard to gauge the accuracy of the vCT. To our knowledge, this study is the first clinical investigation of CBCT in adaptive lung proton therapy.
METHODS AND MATERIALS
Patient selection and data acquisition
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Data from twenty consecutive patients treated for lung malignancies were included in this retrospective study. All patients underwent passive scattering proton therapy (PSPT) using two treatment fields with a median dose of 66.3Gy [CGE] (range:40-66.6Gy [CGE] ) in a median of 1.8Gy/fraction (range:1.5-4Gy/fraction). The patient cohort included a variety of tumor sizes, locations and anatomical changes that occurred throughout the treatment course ( Table 1) . The imaging protocol consisted of a 4D PET/CT for treatment planning, CBCT and rescan 4D CT acquired in treatment position for verification during the course of treatment. The proton-gantry mounted CBCT system (Ion Beam Applications SA, Ottignies-Louvain-la-Neuve, BE) has a sourceto-axis distance of 288.4cm, detector-to-axis distance of 58.6cm and a maximum field-of-view (FoV) of 34cm; the images were acquired in half-scan mode at 110kVp and 1142mAs. The CBCTs were reconstructed with a resolution of 1.33×1.33×2.5mm 3 using the open-source Reconstruction Toolkit (RTK). 20 The average phase of the 4D CT was used for dose calculations. One pair of CBCT and rCT at mid-treatment was selected for evaluation for each patient. The chosen rCT and CBCT scans were acquired on the same day for 17 patients; for 3 they were acquired within 2 days of each other.
Virtual CT and image correction
The CBCT was rigidly aligned to the planning CT (pCT) and the diffeomorphic Morphons deformable image registration (DIR) algorithm available in the open-source REGGUI package was subsequently applied to register the pCT to the CBCT. 21 This method was previously validated for head and neck cancer patients. 16, 17 Some anatomical changes in the thorax cannot be modeled by deformation alone. The situations are diverse, but include changes within the lung (such as atelectasis and pleural effusion) and different tumor responses to treatment (such as regression of infiltrating tumors and erosion 22 ). Therefore, a semi-automatic correction step was applied to the vCT for these anatomical modifications. This step consists of a watershed-cuts algorithm 23, 24 combined with an exclusive OR logical operator and a classifier 25, 26 to identify regions showing significant intensity mismatch between vCT and CBCT.
When appropriate, the vCT intensities were replaced by the bulk value of lung or tissue based on thresholding of the CBCT intensities. This algorithm was validated in-house 27 ; technical details of the implementation can be found as supplementary material.
Clinical indicators: WET and dose warping
A complementary set of clinical indicators, based on WET and dose, that support the replanning decision-making, were used to estimate the impact of anatomical changes on the treatment objectives.
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Variation in WET on the distal surface of the target is a good surrogate for potential under/overranges. Changes in range were estimated by computing the difference between the WET from the pCT and vCT (i.e. WET pCT >WET vCT corresponds to over-ranging and WET pCT <WET vCT to under-ranging).
In PSPT compensator smearing is used to ensure target coverage in presence of errors in patient positioning and motion. 28 Therefore, potential under-ranges are partially taken into account by the compensator; thus, for under-ranges a morphological dilation using the same radius as the compensator is applied on the pCT-based WET map before computing the difference with the vCTbased WET map to identify under-ranges not accounted for in smearing. Quantitative measurements of the 2D WET difference maps at the PTV distal surface (per beam) for the pCT and vCT were calculated as clinical indicators, which include the percentage of pixels with under/over-ranges larger than 3mm (WET under>3mm /WET over>3mm ) and the 95% percentile of the under/over-range distribution (WET under-95% /WET over-95% ).
Complementary to the WET analysis, it is necessary to evaluate the dosimetric impact of under/overranging, particularly for OAR. Online dose review requires a fast dose recalculation tool; thus we validated in-house a fast range-corrected dose approximation method 29 as dose indicators. These were for PTV and iCTV the V 95% and V 99% , respectively, with a threshold of 3% change in the rCT. For OARs the dose tolerances used were: for heart, D max =72Gy, V 45Gy <35%
and V 30Gy <50%; for esophagus, D max =70Gy and V 55Gy <30%; for cord (and cord+5mm), D max =50Gy(65Gy); and for brachialplexus, D max =66Gy. The iCTV/PTV contours were rigidly propagated while the OARs were propagated using DIR.
RESULTS
Case studies of different anatomical changes
Lung changes
Atelectasis is the collapse of lung that is sometimes reversible. PT#1 developed partial atelectasis at the upper left lobe during week two ( 
3.1.2: Tumor changes
Different tumor response scenarios were identified and detailed below.
Infiltrating tumors
For PT#14, the GTV decreased from 4.1 to 2.7cm in diameter after four weeks of treatment (Fig. 3) .
The uncorrected vCT resulted in DIR errors of the lung tissue between the tumor and chest wall. After applying the correction algorithm, the clinical indicators were nearly identical between vCT and rCT
Tumor regression When tumors regress, the topological changes may not be handled by DIR alone. In PT#2 a 22.3mm cavity appeared within the original tumor volume (Fig. 2) . Its size and location were accurately Setup errors should not be confused with systematic drift of tumor position through the treatment course. For PT#5, the primary tumor shifted in the inferior direction, and this was consistent between the CBCT and rCT. DIR accurately described the change in tumor position, but the modest change in WET had minimal effect on target coverage or dose to OAR.
Due to FoV limitations, a minority of CBCTs did not encompass the entire exterior of the patient body at the beam entrance ( Fig. 2 and 3 ). For PT#4, the CBCT truncation resulted in overestimation M A N U S C R I P T
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of over-ranging of the RPO field (WET over-95% =19.1/11.0mm for rCT/vCT), but the overall changes in range and dosimetry were small (Fig. 4) . Nevertheless, uncorrected truncation may in some cases lead to inaccurate clinical indicators (PT#3: iCTV ∆V 99% =-27/-27/-13% and, PT#17: iCTV ∆V 99% =0/0/-5% for D vCT-WET /D vCT /D rCT ).
General results
Eighteen of the twenty patients exhibited tumor regression resulting in over-ranging of the proton beams; two showed considerable under-ranging. These were cases of atelectasis (PT#1) and tumor enlargement (PT#16). For all patients, the average absolute difference in WET over-95% and WET over>3mm between vCT and rCT were 3.4±2.7mm and 12±12%, respectively. Figure 5 shows examples of WET and WET difference maps. WET difference maps identified the same regions of under/over-ranging for all patients with large anatomical changes. This was true even for PT#8 and PT#20, in spite of the full magnitude of the over-ranging not being fully recovered due to limitations of the corrected vCT to reproduce complex shrinkage and/or density changes (Fig. 5) . In cases of smaller changes or setup variations, the WET difference maps were less uniform. In general, values of WET over-95% needed to exceed 15mm before significant dosimetric changes could be detected. The most common issues that could lead to a replan were loss of tumor volume coverage, increase in maximum dose to the cord, and over-ranging of dose into the heart.
DISCUSSION
In proton therapy, accurate Hounsfield units are a requirement to make clinical decisions for ART.
CBCT plays an important role in image-guided therapy, and vCTs is one step in that direction and may play a complementary role to rCT.
In terms of WET information, although the vCT may not reproduce identical WET maps, it identifies the same trends as the rCT regarding the effect of the WET changes. 90% of the fields with WET under-95% /WET over-95% larger than 10mm were properly identified as such from the vCT. The dose warping method reproduced similar clinical indicators for patients with considerable changes that may trigger a replan. The most common issue was loss of target coverage of the iCTV. For PT#1, PT#2 and PT#14, the impact to OARs was detected (esophagus, heart/cord and cord respectively). For PT#8, the changes in OAR dose were not properly detected, while for PT#20 an increase in cord dose was incorrectly detected. When smaller changes occurred, differences in OAR dose were also detected (PT#11, PT#12 and PT#16), but some false positives/negatives occurred for loss of target coverage (PT#13, PT#15 and PT#17). Variations in setup can result in overestimation (PT#9) and underestimation (PT#19) of over-ranging, but with minimal dosimetric impact. In general, OAR doses M A N U S C R I P T
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were maintained within tolerance; however, special care should be given to fields that point towards an OAR, such as lateral oblique fields that may range out at the heart (PT#2, PT#7 and PT#12).
An important conclusion taken from this retrospective investigation was the necessity to evaluate multiple parameters during the ART decision-making process: changes in WET, qualitative review of images and dose distributions, DVHs and corresponding dose-statistics. Flags raised by a single indicator should be backed by additional evidence. For example, iCTV-V 99% statistic was quite sensitive even when the DVHs did not reflect major changes. In cases where the anatomical changes are small the decision to replan should not be based on individual scans, but rather on continued monitoring. Smaller changes can in fact be comparable to setup errors and may average out.
The limitations of the proposed workflow were identified through an evaluation using a diverse cohort of patients. DIR has inherent uncertainties and associated errors, and traditional algorithms are not adequate when tissue appears/disappears (such as atelectasis). If unaccounted for, such situations result in significant errors in WET/range estimation. The correction step works well for gross registration errors, but cannot recover complex changes in tumor topology. When applying the method prospectively and if the correction step is not adequate, manual adjustments to the vCT may be necessary during the second decision-making point (i.e., offline review of vCT). Using CBCT directly for dose recalculation is a viable alternative to remove the errors associated with DIR. Despite the vast work on directly using CBCT in conventional photon therapy 14, 30 and/or to improve CBCT image quality 31, 32 , its usability is still limited in proton therapy 18, 33 and therefore the corrected vCT is a good interim solution. For smaller registration errors, we identified two common patterns of failure:
first, the interface of lung-tissue-bone at the posterior rib wall due scatter artifacts, and second, the positioning of the scapula (which can often move in and out of the path of lateral oblique fields).
From a clinical perspective, two scenarios are possible with DIR errors. The first is a false positive trigger, i.e., the dose calculated on the vCT indicated a change in dosimetry when there is none. The outcome is an unnecessary CT scan to confirm the findings. The other is a false negative trigger, i.e., the dose calculated on the vCT failed to detect the change in dosimetry. While this scenario poses a bigger risk it is unlikely to occur. Higher DIR errors are associated with larger anatomical changes, and in such cases variations in dosimetry are usually still predicted even if with a different magnitude.
The use of CBCT instead of rCT has its own associated challenges. First, subtle changes in density of lung tissues between planning and verification (PT#20) were undetectable on CBCT but apparent on rCT. Second, the limited FoV and artifacts caused by the couch may result in incomplete information of the external contour. This was problematic for some lateral oblique fields (10% of fields); regardless, it can be avoided by closely matching the patient geometry near the beam entrance during M A N U S C R I P T
image acquisition. This is not a limitation of the proposed workflow for CBCT systems with larger FoVs.
We established that a vCT is comparable to rCT; the next step is to test the workflow on a larger cohort and transition the workflow to clinical routine. The clinical indicators investigated here were empirically sensible; yet further investigations are required for defining the appropriate action threshold for replanning. On the technical side, improvement of the workflow to minimize its current limitations is a priority, which includes investigating lung-specialized DIR algorithms, 34 automatic segmentation validation, 19 improvement of CBCT image quality 32 and integration with TPS or using more accurate dose calculations. 
CONCLUSIONS
We retrospectively evaluated a novel workflow to quantitatively assess WET and dose distributions using CBCT for proton therapy. This workflow was shown to provide similar clinical indicators as rCT on patients with considerable interfractional anatomical changes. 
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